The companies have decided to expand their existing collaboration for RNA interference therapies to several Central & Eastern EU countries. The multi-regional agreement will cover countries incl. Poland, the Czech Republic, Hungary, Slovakia, Lithuania, Estonia & Latvia, in addition to Israel
The new agreement was based on the long-term collaboration b/w Alnylam & Medison in Israel. The agreement enables Alnylam to use Medison’s multi-regional platform for RNAi therapies i.e., Onpattro (patisiran), Givlaari (givosiran) & Oxlumo (lumasiran) across additional countries in EU
Givlaari & Oxlumo were approved for reimbursement in Poland while both companies will work together to obtain additional reimbursements in the territories
Ref: Prnewswire | Image: Alnylam
Related News:- Alnylam Reports the US FDA’s Acceptance of sNDA Application Filed for Oxlumo to Treat Advanced Primary Hyperoxaluria
